Philippe Marambaud

List of Publications by Year
in descending order

80 papers	15,074 citations	87888 38 h-index	69250 77 g-index
94 all docs	94 docs citations	94 times ranked	27685 citing authors

#	Article	IF	Citations
1	Extracellular CIRP Activates the IL-6RÎ±/STAT3/Cdk5 Pathway in Neurons. Molecular Neurobiology, 2021, 58, 3628-3640.	4.0	10
2	Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models. Acta Neuropathologica Communications, 2020, 8, 126.	5.2	5
3	Molecular and Pharmacological Modulation of CALHM1 Promote Neuroprotection against Oxygen and Glucose Deprivation in a Model of Hippocampal Slices. Cells, 2020, 9, 664.	4.1	11
4	Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models. Journal of Clinical Investigation, 2020, 130, 942-957.	8.2	48
5	Blockade and knock-out of CALHM1 channels attenuate ischemic brain damage. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1060-1069.	4.3	9
6	Chemical synapses without synaptic vesicles: Purinergic neurotransmission through a CALHM1 channel-mitochondrial signaling complex. Science Signaling, 2018, 11, .	3.6	69
7	Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathologica Communications, 2018, 6, 82.	5.2	34
8	Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology. Human Molecular Genetics, 2017, 26, 4786-4798.	2.9	45
9	CALHM1-Mediated ATP Release and Ciliary Beat Frequency Modulation in Nasal Epithelial Cells. Scientific Reports, 2017, 7, 6687.	3.3	34
10	A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate AÎ² Peptides. Molecular Medicine, 2016, 22, 841-849.	4.4	7
11	ERK1/2 activation in human taste bud cells regulates fatty acid signaling and gustatory perception of fat in mice and humans. FASEB Journal, 2016, 30, 3489-3500.	0.5	30
12	CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice. Scientific Reports, 2016, 6, 24250.	3.3	30
13	AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Scientific Reports, 2016, 6, 26758.	3.3	95
14	Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 121-130.	3.7	23
15	A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10. Scientific Reports, 2016, 6, 37366.	3.3	44
16	Pomalidomide reverses Î³-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood, 2016, 127, 1481-1492.	1.4	75
17	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
18	Stimulation of Brain AMP-Activated Protein Kinase Attenuates Inflammation and Acute Lung Injury in Sepsis. Molecular Medicine, 2015, 21, 637-644.	4.4	22

#	Article	IF	Citations
19	CALHM1 ion channel elicits amyloid-Î² clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain. Journal of Cell Science, 2015, 128, 2330-2338.	2.0	32
20	CALHM1 Deletion in Mice Affects Glossopharyngeal Taste Responses, Food Intake, Body Weight, and Life Span. Chemical Senses, 2015, 40, 373-379.	2.0	10
21	Novel resveratrol analogues attenuate renal ischemic injury in rats. Journal of Surgical Research, 2015, 193, 807-815.	1.6	11
22	Pomalidomide Transcriptionally Reprograms Adult Erythroid Progenitors Independently of Ikaros Proteasomal Degradation. Blood, 2015, 126, 160-160.	1.4	1
23	Effect of the CALHM1 G330D and R154H Human Variants on the Control of Cytosolic Ca2+ and AÎ² Levels. PLoS ONE, 2014, 9, e112484.	2.5	11
24	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Molecular Medicine, 2014, 20, 29-36.	4.4	55
25	Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid Î². Journal of Neuroscience, 2014, 34, 12230-12238.	3.6	143
26	Salty Taste Deficits in CALHM1 Knockout Mice. Chemical Senses, 2014, 39, 515-528.	2.0	38
27	Sucrose-conditioned flavor preferences in sweet ageusic T1r3 and Calhm1 knockout mice. Physiology and Behavior, 2014, 126, 25-29.	2.1	34
28	Overexpression of Extracellular Superoxide Dismutase Protects against Brain Injury Induced by Chronic Hypoxia. PLoS ONE, 2014, 9, e108168.	2.5	24
29	Calcium Homeostasis Modulator (CALHM) Ion Channels: Structure, Functions and Physiological Roles. Membrane, 2014, 39, 41-47.	0.0	0
30	How do taste cells lacking synapses mediate neurotransmission? <scp>CALHM</scp>1, a voltageâ€gated <scp>ATP</scp> channel. BioEssays, 2013, 35, 1111-1118.	2.5	66
31	CALHM1 controls the Ca2+-dependent MEK, ERK, RSK and MSK signaling cascade in neurons. Journal of Cell Science, 2013, 126, 1199-1206.	2.0	35
32	CALHM1 Ion Channel Mediates Purinergic Neurotransmission from Taste Buds to Gustatory Nerve Terminals during Sweet and Bitter Perception. Biophysical Journal, 2013, 104, 631a.	0.5	0
33	CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature, 2013, 495, 223-226.	27.8	405
34	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Molecular Medicine, 2013, 19, 29-36.	4.4	22
35	Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca ²⁺ regulation of neuronal excitability. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1963-71.	7.1	132
36	Identification of potent smallâ€molecule inhibitors of <scp>STAT</scp>3 with antiâ€inflammatory properties in <scp>RAW</scp>Â264.7 macrophages. FEBS Journal, 2012, 279, 3791-3799.	4.7	29

#	Article	IF	Citations
37	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
38	Gas1 Interferes with AÎ²PP Trafficking by Facilitating the Accumulation of Immature AÎ²PP in Endoplasmic Reticulum-Associated Raft Subdomains. Journal of Alzheimer's Disease, 2012, 28, 127-135.	2.6	2
39	Identification and biology of Î±â€secretase. Journal of Neurochemistry, 2012, 120, 34-45.	3.9	77
40	Resveratrol mitigates lipopolysaccharideâ€and AÎ²â€mediated microglial inflammation by inhibiting the TLR4/NFâ€ÎºB/STAT signaling cascade. Journal of Neurochemistry, 2012, 120, 461-472.	3.9	363
41	Overexpression of extracellular superoxide dismutase has a protective role against hyperoxiaâ€induced brain injury in neonatal mice. FEBS Journal, 2012, 279, 871-881.	4.7	26
42	CALHM1 P86L Polymorphism Modulates CSF AÎ² Levels in Cognitively Healthy Individuals at Risk for Alzheimerâ€™s Disease. Molecular Medicine, 2011, 17, 974-979.	4.4	26
43	Small-Molecule Activators of AMP-Activated Protein Kinase (AMPK), RSVA314 and RSVA405, Inhibit Adipogenesis. Molecular Medicine, 2011, 17, 1022-1030.	4.4	75
44	Neuroprotective and metabolic effects of resveratrol: Therapeutic implications for Huntington's disease and other neurodegenerative disorders. Experimental Neurology, 2011, 232, 1-6.	4.1	81
45	AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimerâ€™s disease and other tauopathies. Acta Neuropathologica, 2011, 121, 337-349.	7.7	247
46	Novel synthetic smallâ€molecule activators of AMPK as enhancers of autophagy and amyloidâ€Î² peptide degradation. FASEB Journal, 2011, 25, 219-231.	0.5	209
47	Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-Î² precursor protein. Human Molecular Genetics, 2011, 20, 2026-2036.	2.9	15
48	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
49	AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid-Î² Peptide Metabolism. Journal of Biological Chemistry, 2010, 285, 9100-9113.	3.4	560
50	Letter to the Editor on â€œInvolvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesisâ€ Biochemical and Biophysical Research Communications, 2010, 400, 452.	2.1	1
51	Calcium signaling in neurodegeneration. Molecular Neurodegeneration, 2009, 4, 20.	10.8	258
52	Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants. BMC Research Notes, 2008, 1, 38.	1.4	28
53	A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, AÎ² Levels, and Alzheimer's Disease Risk. Cell, 2008, 133, 1149-1161.	28.9	310
54	Response: CALHM1 Association with Alzheimer's Disease Risk. Cell, 2008, 135, 994-996.	28.9	25

#	Article	IF	Citations
55	Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neuroscience, 2008, 9, S6.	1.9	178
56	CNI-1493 inhibits AÎ² production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. Journal of Experimental Medicine, 2008, 205, 1593-1599.	8.5	21
57	CNI-1493 inhibits AÃŸ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. Journal of Cell Biology, 2008, 182, i1-i1.	5.2	0
58	Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiology of Disease, 2007, 25, 686-696.	4.4	78
59	The Presenilin/Î³-Secretase Complex Regulates Production of Transcriptional Factors: Effects of FAD Mutations. , 2006, , 398-416.		0
60	The cytoplasmic sequence of E-cadherin promotes non-amyloidogenic degradation of Abeta precursors. Journal of Neurochemistry, 2006, 96, 1182-1188.	3.9	17
61	TMP21 is a presenilin complex component that modulates Î³-secretase but not Éµ-secretase activity. Nature, 2006, 440, 1208-1212.	27.8	286
62	Role of peroxisome proliferator-activated receptor Î³ in amyloid precursor protein processing and amyloid Î²-mediated cell death. Biochemical Journal, 2005, 391, 693-698.	3.7	78
63	JLK Inhibitors: Isocoumarin Compounds as Putative Probes to Selectively Target the γ-Secretase Pathway. Current Alzheimer Research, 2005, 2, 327-334.	1.4	10
64	Resveratrol Promotes Clearance of Alzheimer's Disease Amyloid-Î² Peptides. Journal of Biological Chemistry, 2005, 280, 37377-37382.	3.4	669
65	O3-05-02 FAD-linked presenilin-1 mutations affect the N-cadherin/CBP signaling pathway via a loss-of-function mechanism. Neurobiology of Aging, 2004, 25, S61-S62.	3.1	2
66	A CBP Binding Transcriptional Repressor Produced by the PS1/Ïµ-Cleavage of N-Cadherin Is Inhibited by PS1 FAD Mutations. Cell, 2003, 114, 635-645.	28.9	459
67	MÃ©tabolisme du prÃ©curseur du peptide amyloÃ¯de et prÃ©sÃ©nilines. Medecine/Sciences, 2002, 18, 717-724	0.2	7
68	A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO Journal, 2002, 21, 1948-1956.	7.8	621
69	Role of the proteasome in Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 133-138.	3.8	89
70	Presenilinâ€1: A Component of Synaptic and Endothelial Adherens Junctions. Annals of the New York Academy of Sciences, 2000, 920, 209-214.	3.8	13
71	Presenilin-1 Forms Complexes with the Cadherin/Catenin Cellâ€“Cell Adhesion System and Is Recruited to Intercellular and Synaptic Contacts. Molecular Cell, 1999, 4, 893-902.	9.7	221
72	Proteasome Inhibitors Prevent the Degradation of Familial Alzheimerâ€™s Disease-Linked Presenilin 1 and Potentiate Aβ42 Recovery from Human Cells. Molecular Medicine, 1998, 4, 147-157.	4.4	67

#	Article	IF	Citations
73	Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid Î² Peptides: Their Use to Examine the Cell Biology of Presenilins and the Immunohistochemistry of Sporadic Alzheimerâ€™s Disease and Cerebral Amyloid Angiopathy Cases. Molecular Medicine, 1997, 3, 695-707.	4.4	142
74	Cathepsin D displays in vitro Î²-secretase-like specificity. Brain Research, 1997, 750, 11-19.	2.2	94
75	Proteasome Contributes to the Î±â€Secretase Pathway of Amyloid Precursor Protein in Human Cells. Journal of Neurochemistry, 1997, 68, 698-703.	3.9	48
76	Î±â€Secretaseâ€Derived Product of Î²â€Amyloid Precursor Protein Is Decreased by Presenilin 1 Mutations Linked to Familial Alzheimer's Disease. Journal of Neurochemistry, 1997, 69, 2494-2499.	3.9	63
77	Constitutive and Protein Kinase Câ€Regulated Secretory Cleavage of Alzheimer's Î²â€Amyloid Precursor Protein: Different Control of Early and Late Events by the Proteasome. Journal of Neurochemistry, 1997, 69, 2500-2505.	3.9	41
78	Contribution of the Proteasome to the Î±-Secretase Pathway in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 1997, 421, 267-272.	1.6	5
79	Protein Kinase A Phosphorylation of the Proteasome: A Contribution to the Î±â€Secretase Pathway in Human Cells. Journal of Neurochemistry, 1996, 67, 2616-2619.	3.9	36
80	Presenilin-1 is a Regulatory Component of the Cadherin Cell Adhesion Complex: Implications for Alzheimer's Disease. , 0, , 521-530.		1